🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Peking Union Medical College Hospital276 Beijing Tiantan Hospital214 Cancer Institute and Hospital, Chinese Academy of Medical Sciences197 AstraZeneca183 Peking University People's Hospital158
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Beijing

5484 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Active, closed
Efficacy and Safety of Sirolimus in Active Systemic Lupus Erythematosus
NCT04582136Systemic Lupus Erythematosus
Chinese SLE Treatment And Research Group
Phase 3
146
Beijing, Shenzhen, Zhengzhou, Nanchang, Shenyang, Kunming
2021-03-04
Recruiting
China Amyotrophic Lateral Sclerosis Registry of Patients With Traditional Chinese Medicine
NCT04885374Amyotrophic Lateral Sclerosis
Dongzhimen Hospital, Beijing
Observational
2,000
Beijing
2021-03-01
By invitation
Multimodal Artificial Intelligence for Detecting the Psychological State of Cancer Patients
NCT07751757Neoplasm
Chinese PLA General Hospital
Observational
1,500
Beijing
2021-03-01
Recruiting
Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Sintilimab in Clinical Practice Among Chinese Patients
NCT04840355Immune Related Adverse Events, PD-1
Guohui Li
Observational
100
Beijing
2021-02-26
Active, closed
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
NCT04699188KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung
Novartis Pharmaceuticals
Phase 1/2
344
Guangzhou, Beijing
2021-02-24
Active, closed
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT04408638Diffuse Large B-cell Lymphoma
Hoffmann-La Roche
Phase 3
270
Beijing, Guangzhou, Harbin, Shanghai, Tianjin, Wuhan, Zhejiang, Zhengzhou
2021-02-23
Active, closed
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
NCT04279847Myelofibrosis, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome, Myeloproliferative Neoplasm
Incyte Corporation
Phase 1
140
Beijing, Guangzhou, Hangzhou, Zhengzhou
2021-02-23
Active, closed
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
NCT04685135Metastatic Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer
Mirati Therapeutics Inc.
Phase 3
453
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Liuzhou, Harbin, Xinxiang
2021-02-23
Active, closed
Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A
NCT04644575Hemophilia A
Bioverativ, a Sanofi company
Phase 3
261
Beijing, Guangzhou, Hangzhou, Jinan, Kunming, Lanzhou, Suzhou
2021-02-23
Recruiting
Impact of Remimazolam on Prognosis After Bladder Cancer Surgery
NCT04532606Benzodiazepines, Bladder Cancer, Delirium, Surgery
Peking University First Hospital
Phase 4
1,128
Beijing, Beijin, Guiyang, Nanjing, Shanghai
2021-02-05
Active, closed
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
NCT04619004Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Daiichi Sankyo
Phase 2
277
Beijing, Changchun, Chengdu, Guangzhou, Hangzhou, Harbin, Nanjing, Shanghai
2021-02-02
Not yet open
Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway
NCT04736589Breast Cancer
Peking Union Medical College
Phase 3
270
Beijing
2021-02-02
Recruiting
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT04634552Hematological Malignancies
Janssen Research & Development, LLC
Phase 2
510
Beijing, Guangzhou, Hangzhou, Suzhou, Tianjin, Xi'an
2021-02-01
Recruiting
Establishment of a Cohort of Patients With Sepsis-associated Encephalopathy (SAE)
NCT04230447Sepsis-Associated Encephalopathy
Yi Li, MD
Observational
3,000
Beijing
2021-02-01
Recruiting
MR-linac Guided Ultra-hypofractionated RT for Prostate Cancer (SMART-P01 and SMART-P02)
NCT05183074Prostate Cancer, Radiotherapy Side Effect, Magnetic Resonance-linac, Stereotactic Ablative RT
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
50
Beijing
2021-02-01
Recruiting
Protective Effect of CoQ10 Against Negative Inflammatory Response and Organ Dysfunction in Cardiovascular Surgery (PANDA V)
NCT04444349Cardiovascular Disease
Nanjing Medical University
Not applicable
500
Beijing, Guangzhou, Nanjing, Chengdu
2021-02-01
Recruiting
Ticagrelor With Low-dose Versus Regular Aspirin in Patients With Acute Coronary Syndrome (ACS) at High-Risk for Ischemia After Percutaneous Coronary Intervention
NCT04240834Acute Coronary Syndrome, Interventional Cardiology
Fu Wai Hospital, Beijing, China
Phase 4
1,220
Beijing
2021-02-01
Active, closed
A Study of Endovascular Treatment of Femoropopliteal Arterial Occlusive Lesion With Drug-Coated Balloon
NCT04826705Drug-coated Balloon, Femoropopliteal Artery Occlusion, Angioplasty
Liyuan Hospital of Tongji Medical College, Huazhong University of Science and Technology
Observational
2,000
Wuhan, Beijing, Chengdu, Hangzhou, Qingdao, Shanghai, Suzhou
2021-02-01
Active, closed
A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors
NCT04632108Malignant Solid Tumor
Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Phase 1/2
199
Beijing, Linyi
2021-01-28
Active, closed
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
NCT04711252ER-Positive HER2-Negative Breast Cancer
AstraZeneca
Phase 3
1,370
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian
2021-01-28
Active, closed
Intracorporeal Anastomosis Versus Extracorporeal Anastomosis for Left Colon Cancer
NCT04201717Colon Cancer
Jilin University
Not applicable
350
Changchun, Beijing, Chongqing, Guangzhou, Shanghai, Shenyang
2021-01-27
Recruiting
Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer
NCT04415853Esophageal Cancer
Sunshine Lake Pharma Co., Ltd.
Phase 3
416
Beijing
2021-01-21
Active, closed
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
NCT04589845Solid Tumors
Hoffmann-La Roche
Phase 2
920
Beijing, Chengdu, Shanghai, Tianjin, Xi'an
2021-01-18
Recruiting
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
NCT04649242Pediatric Migraine
Pfizer
Phase 3
2,100
Bengbu, Hefei, Beijing, Chongqing, Lanzhou, Shenzhen, Haikou, Shijiazhuang
2021-01-15
Recruiting
Oxaliplatin Combined With S-1(SOX) Neoadjuvant Chemotherapy for Different Cycles in Patients With Gastric Cancer
NCT04483076Gastric Cancer, Chemotherapy Effect
Chinese PLA General Hospital
Phase 3
524
Beijing
2021-01-13
Active, closed
CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma
NCT04718883Mantle Cell Lymphoma
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase 2
59
Beijing, Fuzhou, Guanzhou, Zhengzhou, Nanjing, Shanghai, Tianjin, Hangzhou
2021-01-13
Active, closed
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
NCT04634877Endometrial Neoplasms
Merck Sharp & Dohme LLC
Phase 3
990
Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Nanning, Harbin, Wuhan
2021-01-10
Active, closed
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
NCT04521231B Cell Precursor Acute Lymphoblastic Leukemia
Amgen
Phase 1/2
181
Beijing, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Suzhou, Qingdao, Xi’an
2021-01-04
Recruiting
Clinical Cohort Study in Patients With Different Subtypes of Primary Sjogren Syndrome Related Dry Eye
NCT05605314Dry Eye
Peking University Third Hospital
Observational
500
Beijing
2021-01-01
Recruiting
HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma
NCT06333561Hepatocellular Carcinoma, Lenvatinib, PD-1 Inhibitor, Hepatic Arterial Infusion Chemotherapy
Sun Yat-sen University
Observational
300
Beijing
2021-01-01
Recruiting
Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma
NCT06323382Advanced Hepatocellular Carcinoma, Anti-PD1/PDL1 Antibody, Bevacizumab
Sun Yat-sen University
Observational
240
Beijing
2021-01-01
By invitation
Collect Data From Patients Receiving Standardized Anti-tuberculosis Therapy, Collect Monitoring Data, and Evaluate Treatment Efficacy and Potential Adverse Reactions.
NCT07607288Therapeutic Drug Monitoring (TDM), Tuberculosis
Beijing Chest Hospital
Observational
2,215
Beijing
2021-01-01
Recruiting
Multi-points and Full-thickness Biopsy in the Diagnosis of cCR After Neoadjuvant Therapy for Rectal Cancer
NCT04743102Rectal Cancer, Neoadjuvant Therapy, Complete Remission, Metastasis
Beijing Chao Yang Hospital
Not applicable
260
Beijing
2021-01-01
Recruiting
An MRI-Based Study of Intelligent Pathological Subtyping and Grading of Renal Tumors
NCT07743749Renal Tumor, Kidney Neoplasm
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
900
Beijing
2021-01-01
Recruiting
Protective Effect of Statin Against Negative Cardiovascular Remodeling and Organ Dysfunction After Acute Aortic Syndrome Surgery (PANDA III)
NCT04699279Acute Aortic Syndrome, Aortopathy
Nanjing Medical University
Not applicable
300
Guangzhou, Nanjing, Qingdao, Chengdu, Beijing
2021-01-01
Active, closed
Imaging Markers of High-Risk Plaque Phenotype for Predicting Post-PCI Outcomes
NCT07117084Coronary Artery Disease, Percutaneous Coronary Intervention (PCI), Atherosclerosis of Coronary Artery
Chinese Academy of Medical Sciences, Fuwai Hospital
Observational
2,000
Beijing, Tai’an, Weifang
2021-01-01
Active, closed
Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection
NCT04666272Melanoma
Novartis Pharmaceuticals
Observational
78
Fuzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Kunming, Hangzhou, Beijing
2020-12-31
Recruiting
ATG Individualized Dosing Model in URD-PBSCT.
NCT06572462Cytomegalovirus Infections, Infection Reactivation, Stem Cell Transplant Complications
Chinese PLA General Hospital
Phase 2
30
Beijing
2020-12-31
Not yet open
Lenvatinib and Pembrolizumab in Resectable Mucosal Melanoma
NCT04622566Mucosal Melanoma, Neoadjuvant Treatment
Peking University Cancer Hospital & Institute
Phase 2
26
Beijing
2020-12-30
Active, closed
Guo's Subclavian Artery Reconstruction: The Prospective, Multiple Center Study of WeFlow-Tbranch Stent Graft System(GUEST Study)
NCT04765605Type B Aortic Dissection
Hangzhou Endonom Medtech Co., Ltd.
Not applicable
120
Beijing, Changsha, Chengdu, Foshan, Fuzhou, Guangzhou, Hangzhou, Hefei
2020-12-25
Recruiting
Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia
NCT04684147Relapsed or Refractory Acute Lymphoblastic Leukemia
Juventas Cell Therapy Ltd.
Phase 2
100
Beijing, Chongqing, Guangzhou, Sanhe, Zhengzhou, Wuhan, Xuzhou, Shanghai
2020-12-24
Recruiting
Internal Microstructure of Patent Foramen Ovale Related to Stroke
NCT04686253Patent Foramen Ovale
China National Center for Cardiovascular Diseases
Observational
1,200
Beijing
2020-12-23
Recruiting
Secukinumab Open Label Roll-over Extension Protocol
NCT04638647Autoimmunity, Inflammation
Novartis Pharmaceuticals
Phase 4
1,000
Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Shantou, Shenzhen, Wuhan
2020-12-22
Active, closed
Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)
NCT04656652Non-small Cell Lung Cancer
Daiichi Sankyo
Phase 3
605
Beijing, Changsha, Hangzhou, Hangzou, Heilongjiang, Henan, Hubei, Nanjing
2020-12-21
Active, closed
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
NCT04607421Neoplasms
Pfizer
Phase 3
841
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Wuhan, Changsha, Nanjing
2020-12-21
Recruiting
To Evaluate Safety and Effectiveness of Transcatheter Aortic Valve System in Patients With Severe Aortic Stenosis
NCT04893603Aortic Valve Stenosis
Chengdu Silara Meditech Inc.
Not applicable
120
Beijing
2020-12-16
Active, closed
A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
NCT04351555Non-Small Cell Lung Cancer
AstraZeneca
Phase 3
358
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Kunming, Nanchang
2020-12-16
Active, closed
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
NCT04624204Small Cell Lung Cancer
Merck Sharp & Dohme LLC
Phase 3
672
Beijing, Chongqing, Fuzhou, Xiamen, Shenzhen, Zhengzhou, Wuhan, Changsha
2020-12-08
Active, closed
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
NCT04658862Urinary Bladder Neoplasms
Janssen Research & Development, LLC
Phase 3
518
Beijing, Changchun, Changsha, Changsha Shi, Chengdu, Chongqing, Guangzhou, Hangzhou
2020-12-07
Active, closed
Discovering Urinary Protein Biomarkers for Hepatocellular Carcinoma in Chronic Hepatitis B Population
NCT06379334Hepatocellular Carcinoma, Hepatitis B
Peking Union Medical College Hospital
Observational
180
Beijing
2020-12-06
Active, closed
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)
NCT04622319HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer
Daiichi Sankyo
Phase 3
1,600
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin
2020-12-04
Active, closed
A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease
NCT04540497IgG4 Related Disease
Amgen
Phase 3
135
Hohhot, Beijing, Guandong, Shang’ai, Shenyang, Wuhan
2020-12-04
Recruiting
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
NCT04613596Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
Mirati Therapeutics Inc.
Phase 2/3
626
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shenzhen
2020-12-02
Active, closed
Study on the Treatment of Differentiated Thyroid Carcinoma with Anlotinib
NCT05007093DTC - Differentiated Thyroid Cancer
Yansong Lin
Phase 2
20
Beijing
2020-12-01
Recruiting
OH2 Injection in Combination With HX008 for Melanoma.
NCT04616443Melanoma
Binhui Biopharmaceutical Co., Ltd.
Phase 1/2
60
Beijing
2020-12-01
Active, closed
Postoperative Thrombosis Prevention in Patients With CD
NCT04486859Cushing Disease, DVT, Pulmonary Embolism
Huashan Hospital
Not applicable
206
Fuzhou, Guangzhou, Wuhan, Shanghai, Chengdu, Ürümqi, Beijing
2020-12-01
Recruiting
Durg Coated Balloon Angioplasty in Infrapopliteal Lesions
NCT05620095Arteriosclerosis, Peripheral Artery Disease, Chronic Limb Threatening Ischemia
Liyuan Hospital of Tongji Medical College, Huazhong University of Science and Technology
Observational
1,000
Beijing, Wuhan, Suzhou, Qingdao, Shanghai, Chengdu, Hangzhou
2020-12-01
Recruiting
PUMCH Dementia Longitudinal Cohort Study
NCT05023564Dementia, Dementia, Vascular, Dementia With Lewy Bodies, Dementia, Mixed
Peking Union Medical College Hospital
Observational
20,000
Beijing
2020-12-01
Not yet open
A Real-world Study Evaluating the Usage of Camrelizumab in Chinese Patients With Advanced Esophageal Cancer
NCT04616040Esophageal Cancer
Peking University
Observational
1,030
Beijing
2020-12-01
Active, closed
Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)
NCT04639986Metastatic Breast Cancer
Gilead Sciences
Phase 3
331
Beijing, Changchun, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan
2020-11-23
Recruiting
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
NCT04606446Locally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Non-small Cell Lung Cancer
Pfizer
Phase 2
320
Beijing, Guangzhou, Changchun, Xi'an
2020-11-16
Active, closed
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
NCT04644068Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer
AstraZeneca
Phase 1/2
702
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Harbin, Jining
2020-11-12
Active, closed
A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors
NCT04606472Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
60
Beijing, Chongqing, Xiamen, Zhengzhou, Wuhan, Shanghai, Chengdu
2020-11-10
Active, closed
Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia
NCT04606433Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
47
Hefei, Beijing, Chongqing, Guangzhou, Changsha, Shanghai, Tianjin, Hangzhou
2020-11-04
Active, closed
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)
NCT04512235AL Amyloidosis
Alexion Pharmaceuticals, Inc.
Phase 3
281
Beijing, Guangzhou, Hangzhou, Shanghai, Suzhou, Wenzhou, Wuhan
2020-11-03
Active, closed
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
NCT04524871Advanced Liver Cancers
Hoffmann-La Roche
Phase 1/2
518
Beijing, Shanghai
2020-11-01
Recruiting
Diagnosis and OutcoMes evaluAtIoN of Multicenter Patients With HFpEF Using Multimodality Imaging
NCT04602338Heart Failure, Diastolic, Multicenter Study
Chinese Academy of Medical Sciences, Fuwai Hospital
Observational
1,000
Beijing
2020-11-01
Recruiting
Apatinib Combined with Temozolomide and Etoposide Capsules in the Treatment of Recurrent Medulloblastoma in Children
NCT04501718Recurrent Medulloblastoma
Beijing Sanbo Brain Hospital
Phase 2
44
Beijing
2020-10-28
Recruiting
Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT04586478Non-Hodgkin's Lymphoma
Juventas Cell Therapy Ltd.
Phase 2
60
Beijing, Chongqing, Guangzhou, Zhengzhou, Wuhan, Jinan, Shanghai, Chengdu
2020-10-26
Active, closed
Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments
NCT04454437Metastatic Triple-negative Breast Cancer
Gilead Sciences
Phase 2
80
Beijing, Shenyang, Hangzhou, Changchun, Changsha, Chengdu, Chongqing, Guangzhou
2020-10-23
Active, closed
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection
NCT04581473Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma
CARsgen Therapeutics Co., Ltd.
Phase 1/2
192
Hefei, Beijing, Fuzhou, Shenzhen, Harbin, Zhengzhou, Wuhan, Nanjing
2020-10-23
Active, closed
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
NCT04464226Cancer
Bayer
Phase 3
402
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Shantou, Shenzhen
2020-10-20
Active, closed
Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC
NCT04550260Esophageal Squamous Cell Carcinoma
AstraZeneca
Phase 3
640
Anyang, Beijing, Bengbu, Changsha, Changzhi, Chengdu, Chongqing, Fuzhou
2020-10-19
Active, closed
Myasthenia Gravis Inebilizumab Trial
NCT04524273Myasthenia Gravis
Amgen
Phase 3
238
Beijing, Guiyang, Hunan, Jinan, Shanghai, Suzhou, Tianjin, Xi'an
2020-10-15
Active, closed
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
NCT04538664Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC
Phase 3
308
Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou
2020-10-13
Active, closed
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
NCT04546009Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
Hoffmann-La Roche
Phase 3
992
Anyang, Baoding, Beijing, Bengbu, Changchun, Changsha, Fujian, Guangzhou
2020-10-09
Active, closed
A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors
NCT04434092Paroxysmal Nocturnal Hemoglobinuria
Hoffmann-La Roche
Phase 3
210
Beijing, Guangzhou, Hangzhou, Nanjing, Nantong, Shanghai, Wuhan
2020-10-08
Active, closed
A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)
NCT04529772Diffuse Large B-Cell Lymphoma
Acerta Pharma BV
Phase 3
611
Beijing, Changchun, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Luoyang
2020-10-08
Active, closed
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
NCT04484623Multiple Myeloma
GlaxoSmithKline
Phase 3
302
Beijing, Changchun, Changsha, Guangzhou, Hangzhou, Jiangsu, Nanchang, Shenyang
2020-10-01
Recruiting
China Imaging-based Biobank of Cerebral Small Vessal Diseases
NCT04962295Cerebral Small Vessel Diseases
Peking University Third Hospital
Observational
10,000
Beijing
2020-10-01
Active, closed
Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)
NCT04524611Crohn's Disease (CD)
AbbVie
Phase 3
527
Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Zhengzhou, Wuhan, Changsha
2020-09-30
Active, closed
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT04487080Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC
Phase 3
1,074
Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Guangzhou, Hangzhou
2020-09-30
Active, closed
Biweekly Actinomycin-D Treatment or Multi-day Methotrexate Protocol in Low-risk Gestational Trophoblastic Neoplasia
NCT04562558Gestational Trophoblastic Tumor, Gestational Trophoblastic Neoplasia, Stage I Gestational Trophoblastic Tumor, Stage II Gestational Trophoblastic Tumor
xiang yang
Not applicable
228
Beijing
2020-09-29
Recruiting
Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML
NCT04501120Relapsed/Refractory Acute Myeloid Leukaemia, Myeloid Malignancy
Ascentage Pharma Group Inc.
Phase 1/2
682
Beijing, Chongqing, Guangzhou, Zhengzhou, Wuhan, Changsha, Suzhou, Shanghai
2020-09-28
Recruiting
A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
NCT04685226Solid Tumors
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1/2
310
Hefei, Beijing, Guangzhou, Zhuhai, Guangdong, Shijiazhuang, Harbin, Luoyang
2020-09-27
Active, closed
A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT
NCT04488822Tenosynovial Giant Cell Tumor
Daiichi Sankyo Co., Ltd.
Phase 3
40
Beijing, Guangzhou, Hangzhou, Shanghai
2020-09-25
Recruiting
Phase Ib Clinical Study of Keynatinib
NCT04807881Lymphoma, B-Cell
Medolution Ltd.
Phase 1
75
Beijing, Shanghai, Chengdu
2020-09-24
Active, closed
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)
NCT04497844Prostatic Neoplasms
Janssen Research & Development, LLC
Phase 3
696
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Nanchang, Nanjing, Ningbo
2020-09-23
Active, closed
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
NCT04557449Liposarcoma, Prostate Cancer, Breast Neoplasms, Adenocarcinoma of Lung
Pfizer
Phase 2
362
Beijing, Zhengzhou, Wuhan, Xi’an, Hangzhou
2020-09-23
Active, closed
Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer
NCT04560127Radioactive Iodine-refractory Differentiated Thyroid Cancer
Peking Union Medical College Hospital
Phase 2
20
Beijing
2020-09-23
Active, closed
Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
NCT04584008Biliary Tract Neoplasms, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Colorectal Cancer
Peking University
Not applicable
600
Beijing
2020-09-23
Recruiting
Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC
NCT04342910Gastric Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
550
Beijing
2020-09-21
Active, closed
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)
NCT04280718Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
argenx
Phase 2
229
Beijing, Changsha, Chengdu, Chifeng, Fuzhou, Guangzhou, Guanzhou, Guiyang
2020-09-18
Active, closed
A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT04557098Hematological Malignancies
Janssen Research & Development, LLC
Phase 2
194
Beijing, Chengdu, Guangzhou, Hangzhou, Shanghai, Shenyang, Tianjin, Xi'an
2020-09-17
Active, closed
Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT04384484Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
ADC Therapeutics S.A.
Phase 3
440
Beijing, Xiamen, Guangzhou, Zhengzhou, Changchun, Dalian, Shanghai, Chengdu
2020-09-16
Active, closed
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
NCT04401748Myelodysplastic Syndrome (MDS)
AbbVie
Phase 3
531
Beijing, Lanzhou, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Nanjing, Suzhou
2020-09-10
Recruiting
Evaluate the Safety and Clinical Activity of HH2853
NCT04390737FL Lymphoma, Epithelioid Sarcoma, Peripheral T Cell Lymphoma, Advanced Solid Tumor
Haihe Biopharma Co., Ltd.
Phase 1/2
254
Hefei, Beijing, Guangzhou, Nanning, Zhengzhou, Wuhan, Changsha, Nanjing
2020-09-08
Active, closed
A Phase 1 Study of TRS005 in Patients With R/R CD20-positive B-NHL.
NCT05395533CD20-positive B-cell Non-Hodgkin Lymphoma
Zhejiang Teruisi Pharmaceutical Inc.
Phase 1
147
Beijing, Guangzhou, Zhengzhou, Suzhou, Tianjin
2020-09-08
Recruiting
Atrial Fibrillation Patients Treated With Catheter Ablation
NCT05266144Atrial Fibrillation, Atrial Fibrillation Recurrent
Peking Union Medical College Hospital
Observational
300
Beijing
2020-09-04
Recruiting
HMPL-453 Tartrate in Advanced Intrahepatic Cholangiocarcinoma
NCT04353375Advanced Intrahepatic Cholangiocarcinoma, Solid Tumor, Adult
Hutchmed
Phase 2/3
235
Beijing
2020-09-03
Rows per page Showing 5001–5100 of 5484
Previous 49 50 51 52 53 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/beijing?page=51

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 5,484 of those studies with a site in Beijing.

How many clinical trials are recruiting in Beijing?

3,341 of the 5,484 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 966 have not yet opened recruitment, 1,001 are active but closed to new participants, and 176 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.